CeriBell (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 3,372 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $15.03, for a total transaction of $50,681.16. Following the transaction, the chief executive officer now owns 743,079 shares in the company, valued at approximately $11,168,477.37. The trade was a 0.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
CeriBell Stock Performance
Shares of CBLL stock opened at $14.93 on Tuesday. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75. The business's fifty day simple moving average is $20.16.
CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The firm had revenue of $18.53 million during the quarter, compared to analyst estimates of $17.55 million. On average, analysts predict that CeriBell will post -2.46 earnings per share for the current year.
Institutional Investors Weigh In On CeriBell
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new stake in CeriBell during the 4th quarter worth about $32,000. Summit Investment Advisors Inc. purchased a new stake in CeriBell in the fourth quarter valued at approximately $33,000. Tower Research Capital LLC TRC purchased a new position in CeriBell during the 4th quarter worth approximately $37,000. BNP Paribas Financial Markets purchased a new stake in shares of CeriBell in the 4th quarter valued at $43,000. Finally, PNC Financial Services Group Inc. purchased a new position in shares of CeriBell during the fourth quarter worth $47,000.
Analyst Upgrades and Downgrades
CBLL has been the topic of a number of recent research reports. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a research note on Friday, April 4th. They set a "buy" rating and a $32.00 price objective on the stock. Canaccord Genuity Group restated a "buy" rating and set a $33.00 target price on shares of CeriBell in a report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, CeriBell has a consensus rating of "Buy" and an average price target of $32.50.
Check Out Our Latest Analysis on CBLL
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
